3'-N-(demethyl)-3'-N-[3-({4-[(7-chloro-4-quinolinyl)amino]butanoyl}amino)propyl]-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A | 1236121-81-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3'-N-(demethyl)-3'-N-[3-({4-[(7-chloro-4-quinolinyl)amino]butanoyl}amino)propyl]-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A
• 英文别名: 4-[(7-chloro-4-quinolyl)amino]-N-[3-[[(2S,3R,4S,6R)-2-[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-3-hydroxy-6-methyl-tetrahydropyran-4-yl]-methyl-amino]propyl]butanamide；4-[(7-chloroquinolin-4-yl)amino]-N-[3-[[(2S,3R,4S,6R)-2-[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-3-hydroxy-6-methyloxan-4-yl]-methylamino]propyl]butanamide
• CAS: 1236121-81-5
• 化学式: C₅₃H₈₈ClN₅O₁₃
• 分子量: 1038.76
• InChiKey: QKOSEVHGBDPNKZ-QYHWOGKCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  72
• 可旋转键数：
  16
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  234
• 氢给体数：
  7
• 氢受体数：
  17

反应信息

• 作为反应物：
  描述：

  3'-N-(demethyl)-3'-N-[3-({4-[(7-chloro-4-quinolinyl)amino]butanoyl}amino)propyl]-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A 在 palladium 10% on activated carbon 氢气 作用下， 以 乙醇 为溶剂， 反应 4.0h， 生成 3'-N-(demethyl)-3'-N-[3-({4-[(4-quinolinyl)amino]butanoyl}amino)propyl]-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A
  参考文献：
  名称：

  [EN] 3'-N-SUBSTITUTED 9-DEOXO-9A-METHYL-9A-AZA-HOMOERYTHROMYCIN HAVING ANTIMALARIAL ACTIVITY
  [FR] 9-DÉOXO-9A-MÉTHYL-9A-AZAHOMOÉRYTHROMYCINE 3'-N-SUBSTITUÉE AYANT UNE ACTIVITÉ ANTIPALUDIQUE

  摘要：

  本发明涉及具有抗疟疾活性的新型3'-N-取代9-去氧-9a-甲基-9a-氮杂-9a-同麦红霉素A衍生物。更具体地，本发明涉及具有抗疟疾活性的3'-N-取代9-去氧-9a-甲基-9a-氮杂-9a-同麦红霉素A和3'-N-取代3-O-去氯鼠杆菌素-9-去氧-9a-甲基-9a-氮杂-9a-同麦红霉素A衍生物，以及它们的制备中间体、制备方法、用作治疗剂的用途以及具有抗疟疾活性的盐。

  公开号：

  WO2010086351A1
• 作为产物：
  描述：

  阿奇霉素 在 platinum(IV) oxide 、 氢气 、 1-羟基苯并三唑 、 溶剂黄146 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 偶氮二甲酸二乙酯 作用下， 以 二氯甲烷 、 丙酮 、 甲苯 为溶剂， 20.0 ℃ 、500.01 kPa 条件下， 反应 68.0h， 生成 3'-N-(demethyl)-3'-N-[3-({4-[(7-chloro-4-quinolinyl)amino]butanoyl}amino)propyl]-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A
  参考文献：
  名称：

  Novel hybrid molecules based on 15-membered azalide as potential antimalarial agents

  摘要：

  Malaria remains the most prevalent tropical disease, and due to the spread of resistant parasites novel therapeutics are urgently needed. Azithromycin has shown potential in malaria treatment so we designed hybrid azalide molecules with the aim to improve activity against and selectivity for the malaria parasite. Novel hybrid molecules comprising 4-aminoquinoline moiety covalently liked to 15-membered azalide scaffold at position C-3' were synthesized and biologically evaluated. Antimalarial testing against Plasmodium falciparum sensitive and resistant strains confirmed the improved in vitro activity over azithromycin and chloroquine. Selectivity of the compounds (HepG2 IC50/P. falciparum IC50 ratio) for the parasite was high (100-2700) and their antibacterial activity diminished. Even though oral bioavailability determined for compound 12 was low, novel quinoline C-3'-substituted 15-membered azalides represent an interesting subclass of antimalarial macrolides that need further research and evaluation. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.01.039

文献信息

• [EN] 3'-N-SUBSTITUTED 9-DEOXO-9A-METHYL-9A-AZA-HOMOERYTHROMYCIN HAVING ANTIMALARIAL ACTIVITY<br/>[FR] 9-DÉOXO-9A-MÉTHYL-9A-AZAHOMOÉRYTHROMYCINE 3'-N-SUBSTITUÉE AYANT UNE ACTIVITÉ ANTIPALUDIQUE
  申请人：GLAXOSMITHKLINE ZAGREB

  公开号：WO2010086351A1

  公开（公告）日：2010-08-05

  The present invention relates to novel 3'-N-substituted 9-deoxo-9a-methyl-9a-aza-9a- homoerythromycin A derivatives having antimalarial activity. More particularly, the invention relates to 3'-N-substituted-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A and 3'-N-substituted-3-O-decladinosyl-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A derivatives having antimalarial activity, to the intermediates for their preparation, to the methods for their preparation, to their use as therapeutic agents, and to salts thereof having antimalarial activity.

  本发明涉及具有抗疟疾活性的新型3'-N-取代9-去氧-9a-甲基-9a-氮杂-9a-同麦红霉素A衍生物。更具体地，本发明涉及具有抗疟疾活性的3'-N-取代9-去氧-9a-甲基-9a-氮杂-9a-同麦红霉素A和3'-N-取代3-O-去氯鼠杆菌素-9-去氧-9a-甲基-9a-氮杂-9a-同麦红霉素A衍生物，以及它们的制备中间体、制备方法、用作治疗剂的用途以及具有抗疟疾活性的盐。
• Novel hybrid molecules based on 15-membered azalide as potential antimalarial agents
  作者：Kristina Starčević、Dijana Pešić、Ana Toplak、Goran Landek、Sulejman Alihodžić、Esperanza Herreros、Santiago Ferrer、Radan Spaventi、Mihaela Perić

  DOI：10.1016/j.ejmech.2012.01.039

  日期：2012.3

  Malaria remains the most prevalent tropical disease, and due to the spread of resistant parasites novel therapeutics are urgently needed. Azithromycin has shown potential in malaria treatment so we designed hybrid azalide molecules with the aim to improve activity against and selectivity for the malaria parasite. Novel hybrid molecules comprising 4-aminoquinoline moiety covalently liked to 15-membered azalide scaffold at position C-3' were synthesized and biologically evaluated. Antimalarial testing against Plasmodium falciparum sensitive and resistant strains confirmed the improved in vitro activity over azithromycin and chloroquine. Selectivity of the compounds (HepG2 IC50/P. falciparum IC50 ratio) for the parasite was high (100-2700) and their antibacterial activity diminished. Even though oral bioavailability determined for compound 12 was low, novel quinoline C-3'-substituted 15-membered azalides represent an interesting subclass of antimalarial macrolides that need further research and evaluation. (C) 2012 Elsevier Masson SAS. All rights reserved.